Abstract

Mirtazapine is a noradrenergic and specific serotonergic antidepressant, characterized by a unique pharmacologic profile, favorable pharmacokinetics, and proven efficacy and safety. Mirtazapine has demonstrated clinical efficacy in the treatment of moderately and severely depressed patients. In addition, mirtazapine was found to be equally effective as clomipramine in the treatment of severely depressed, hospitalized patients. The overall improvement with mirtazapine is seen after 1 week of treatment and is sustained throughout the treatment period. It is paralleled by an improvement in depressed mood, the core symptom of depressive illness. Because of its unique pharmacologic profile, mirtazapine is virtually devoid of anticholinergic, adrenolytic, and serotonin-related side effects. The most frequently reported adverse events were transient sedation and weight gain.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.